GRTX — Galera Therapeutics Share Price
0.000.00%
Last trade - 00:00- $10.01m
- $142.80m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -232.53% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 124.53 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in cancer. The Company’s lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Company’s second product candidate, rucosopasem manganese (rucosopasem), is in development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Rucosopasem is an orphan drug designation and orphan medicinal product designation for the treatment of pancreatic cancer.
Directors
- Michael Powell NEC (66)
- J. Mel Sorensen PRE (64)
- Christopher Degnan CFO (41)
- Robert Beardsley COO (60)
- Joel Sussman CAO (72)
- Arthur Fratamico OTH (55)
- Jon Holmlund OTH (64)
- Emmett Cunningham DRC (60)
- Lawrence Alleva IND (71)
- Kevin Lokay IND (64)
- Linda West IND (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 19th, 2012
- Public Since
- November 7th, 2019
- No. of Shareholders
- 12
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 54,392,170
- Address
- 45 Liberty Blvd., Suite 230, MALVERN, 19355
- Web
- https://www.galeratx.com/
- Phone
- +1 6107251500
- Auditors
- KPMG LLP
Upcoming Events for GRTX
Galera Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Galera Therapeutics Inc Earnings Release
Similar to GRTX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Galera Therapeutics share price?
As of Today at 19:09 UTC, shares in Galera Therapeutics are trading at $0.18. This share price information is delayed by 15 minutes.
How has the Galera Therapeutics share price performed this year?
Shares in Galera Therapeutics last closed at $0.18 and the price had moved by -93.41% over the past 365 days. In terms of relative price strength the Galera Therapeutics share price has underperformed the S&P500 Index by -94.51% over the past year.
What are the analyst and broker recommendations for Galera Therapeutics?
The overall consensus recommendation for Galera Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Galera Therapeutics dividend yield?
Galera Therapeutics does not currently pay a dividend.
Does Galera Therapeutics pay a dividend?
Galera Therapeutics does not currently pay a dividend.
When does Galera Therapeutics next pay dividends?
Galera Therapeutics does not currently pay a dividend.
How do I buy Galera Therapeutics shares?
To buy shares in Galera Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Galera Therapeutics?
As of the previous close price of $0.18, shares in Galera Therapeutics had a market capitalisation of $10.01m.
Where are Galera Therapeutics shares listed?
Here are the trading details for Galera Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: GRTX
What kind of share is Galera Therapeutics?
Based on an overall assessment of its quality, value and momentum Galera Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Galera Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Galera Therapeutics is $0.50. That is 171.74% above the last closing price of $0.18.
Analysts covering Galera Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.24 for the next financial year.
What is the trend in the Galera Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Galera Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -31.21%.
As of the last closing price of $0.18, shares in Galera Therapeutics were trading -61.91% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Galera Therapeutics PE Ratio?
The Galera Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Galera Therapeutics?
Galera Therapeutics' management team is headed by:
- Michael Powell - NEC
- J. Mel Sorensen - PRE
- Christopher Degnan - CFO
- Robert Beardsley - COO
- Joel Sussman - CAO
- Arthur Fratamico - OTH
- Jon Holmlund - OTH
- Emmett Cunningham - DRC
- Lawrence Alleva - IND
- Kevin Lokay - IND
- Linda West - IND